25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Buy, Hold or Sell?

Let's analyze Sinopep together

I guess you are interested in Sinopep-Allsino Biopharmaceutical Co. Ltd. A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Sinopep-Allsino Biopharmaceutical Co. Ltd. A

I send you an email if I find something interesting about Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

1. Quick Overview

1.1. Quick analysis of Sinopep (30 sec.)










1.2. What can you expect buying and holding a share of Sinopep? (30 sec.)

How much money do you get?

How much money do you get?
¥0.08
When do you have the money?
1 year
How often do you get paid?
85.0%

What is your share worth?

Current worth
¥12.01
Expected worth in 1 year
¥14.98
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
¥3.57
Return On Investment
6.4%

For what price can you sell your share?

Current Price per Share
¥55.45
Expected price per share
¥48.30 - ¥68.18
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Sinopep (5 min.)




Live pricePrice per Share (EOD)
¥55.45
Intrinsic Value Per Share
¥-57.43 - ¥-68.30
Total Value Per Share
¥-45.42 - ¥-56.29

2.2. Growth of Sinopep (5 min.)




Is Sinopep growing?

Current yearPrevious yearGrowGrow %
How rich?$362.3m$266.9m$59.7m18.3%

How much money is Sinopep making?

Current yearPrevious yearGrowGrow %
Making money$14.4m$5.7m$8.7m60.2%
Net Profit Margin25.9%16.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Sinopep (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Sinopep?

Welcome investor! Sinopep's management wants to use your money to grow the business. In return you get a share of Sinopep.

First you should know what it really means to hold a share of Sinopep. And how you can make/lose money.

Speculation

The Price per Share of Sinopep is ¥55.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sinopep.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sinopep, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥12.01. Based on the TTM, the Book Value Change Per Share is ¥0.74 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.15 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sinopep.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.080.1%0.070.1%0.030.0%0.030.1%0.030.1%
Usd Book Value Change Per Share0.140.2%0.100.2%0.020.0%0.080.1%0.080.1%
Usd Dividend Per Share0.020.0%0.020.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.150.3%0.120.2%0.030.1%0.090.2%0.090.2%
Usd Price Per Share9.44-8.41-4.35-4.29-4.29-
Price to Earnings Ratio30.71-33.98-57.19-57.97-57.97-
Price-to-Total Gains Ratio60.99-79.13-196.45-198.55-198.55-
Price to Book Ratio5.73-5.62-3.58-3.39-3.39-
Price-to-Total Gains Ratio60.99-79.13-196.45-198.55-198.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.613285
Number of shares131
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share0.100.08
Usd Total Gains Per Share0.120.09
Gains per Quarter (131 shares)16.0511.76
Gains per Year (131 shares)64.1947.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
111535444337
22110711888684
33216018212130131
44321424615173178
55426731019216225
66432137423259272
77537443827302319
88642850231346366
99648156635389413
1010753563039432460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%20.00.00.0100.0%20.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.02.01.085.0%17.02.01.085.0%17.02.01.085.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%17.00.03.085.0%17.00.03.085.0%17.00.03.085.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%20.00.00.0100.0%20.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Sinopep-Allsino Biopharmaceutical Co. Ltd. A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9940.743+34%0.154+548%0.600+66%0.600+66%
Book Value Per Share--12.00810.826+11%8.847+36%7.637+57%7.637+57%
Current Ratio--1.2751.410-10%1.608-21%1.947-35%1.947-35%
Debt To Asset Ratio--0.4060.394+3%0.268+52%0.276+47%0.276+47%
Debt To Equity Ratio--0.6890.656+5%0.371+86%0.403+71%0.403+71%
Dividend Per Share--0.1340.149-10%0.064+110%0.054+150%0.054+150%
Enterprise Value--13315098291.56011903104138.690+12%6504153833.290+105%9342113749.593+43%9342113749.593+43%
Eps--0.5600.479+17%0.191+194%0.202+177%0.202+177%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--7.9117.458+6%6.887+15%11.213-29%11.213-29%
Free Cash Flow Per Share---1.152-0.563-51%-0.524-54%-0.367-68%-0.367-68%
Free Cash Flow To Equity Per Share---1.152-0.563-51%-0.395-66%-0.150-87%-0.150-87%
Gross Profit Margin--1.0001.0000%0.756+32%0.820+22%0.820+22%
Intrinsic Value_10Y_max---68.303--------
Intrinsic Value_10Y_min---57.427--------
Intrinsic Value_1Y_max---2.730--------
Intrinsic Value_1Y_min---2.679--------
Intrinsic Value_3Y_max---11.338--------
Intrinsic Value_3Y_min---10.761--------
Intrinsic Value_5Y_max---23.727--------
Intrinsic Value_5Y_min---21.753--------
Market Cap12186801000.000-24%15118666200.00013454931600.000+12%6968124900.000+117%6865487640.000+120%6865487640.000+120%
Net Profit Margin--0.2930.259+13%0.163+79%0.183+60%0.183+60%
Operating Margin----0%0.110-100%0.048-100%0.048-100%
Operating Ratio--0.9001.003-10%0.943-5%0.773+16%0.773+16%
Pb Ratio4.618-24%5.7295.618+2%3.578+60%3.394+69%3.394+69%
Pe Ratio24.753-24%30.70833.979-10%57.195-46%57.971-47%57.971-47%
Price Per Share55.450-24%68.79061.220+12%31.705+117%31.238+120%31.238+120%
Price To Free Cash Flow Ratio-12.032+19%-14.926-43.688+193%-15.107+1%-14.265-4%-14.265-4%
Price To Total Gains Ratio49.160-24%60.98779.127-23%196.446-69%198.546-69%198.546-69%
Quick Ratio--0.4580.450+2%0.846-46%1.212-62%1.212-62%
Return On Assets--0.0280.026+5%0.016+75%0.018+56%0.018+56%
Return On Equity--0.0470.044+7%0.022+117%0.026+81%0.026+81%
Total Gains Per Share--1.1280.892+26%0.217+419%0.654+72%0.654+72%
Usd Book Value--362340413.860326680215.914+11%266966924.656+36%230447283.114+57%230447283.114+57%
Usd Book Value Change Per Share--0.1360.102+34%0.021+548%0.082+66%0.082+66%
Usd Book Value Per Share--1.6491.486+11%1.215+36%1.049+57%1.049+57%
Usd Dividend Per Share--0.0180.020-10%0.009+110%0.007+150%0.007+150%
Usd Enterprise Value--1828162995.4311634296198.242+12%893020321.311+105%1282672217.819+43%1282672217.819+43%
Usd Eps--0.0770.066+17%0.026+194%0.028+177%0.028+177%
Usd Free Cash Flow---34767093.254-16974170.179-51%-15819217.139-54%-11070070.850-68%-11070070.850-68%
Usd Free Cash Flow Per Share---0.158-0.077-51%-0.072-54%-0.050-68%-0.050-68%
Usd Free Cash Flow To Equity Per Share---0.158-0.077-51%-0.054-66%-0.021-87%-0.021-87%
Usd Market Cap1673247777.300-24%2075792869.2601847362108.680+12%956723548.770+117%942631452.972+120%942631452.972+120%
Usd Price Per Share7.613-24%9.4458.406+12%4.353+117%4.289+120%4.289+120%
Usd Profit--16899643.95714466969.834+17%5753710.694+194%6099230.289+177%6099230.289+177%
Usd Revenue--57769529.41154107681.054+7%33587678.769+72%29162565.317+98%29162565.317+98%
Usd Total Gains Per Share--0.1550.123+26%0.030+419%0.090+72%0.090+72%
 EOD+3 -5MRQTTM+23 -14YOY+25 -145Y+24 -1510Y+24 -15

3.3 Fundamental Score

Let's check the fundamental score of Sinopep-Allsino Biopharmaceutical Co. Ltd. A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1524.753
Price to Book Ratio (EOD)Between0-14.618
Net Profit Margin (MRQ)Greater than00.293
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.458
Current Ratio (MRQ)Greater than11.275
Debt to Asset Ratio (MRQ)Less than10.406
Debt to Equity Ratio (MRQ)Less than10.689
Return on Equity (MRQ)Greater than0.150.047
Return on Assets (MRQ)Greater than0.050.028
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Sinopep-Allsino Biopharmaceutical Co. Ltd. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.763
Ma 20Greater thanMa 5050.940
Ma 50Greater thanMa 10050.824
Ma 100Greater thanMa 20053.214
OpenGreater thanClose53.460
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Sinopep-Allsino Biopharmaceutical Co. Ltd. A

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers APIs, including peptides, small molecules, and oligonucleotides; and intermediate products, such as fulvestrant, oseltamivir, and other intermediates. It also provides CRDMO/CMO services. The company was founded in 2009 and is headquartered in Hangzhou City, China.

Fundamental data was last updated by Penke on 2025-02-23 11:19:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Sinopep earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • A Net Profit Margin of 29.3% means that ¥0.29 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 29.3%. The company is making a huge profit. +2
  • The TTM is 25.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ29.3%TTM25.9%+3.3%
TTM25.9%YOY16.3%+9.6%
TTM25.9%5Y18.3%+7.6%
5Y18.3%10Y18.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.3%-101.0%+130.3%
TTM25.9%-203.6%+229.5%
YOY16.3%-199.0%+215.3%
5Y18.3%-333.8%+352.1%
10Y18.3%-481.5%+499.8%
4.3.1.2. Return on Assets

Shows how efficient Sinopep is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • 2.8% Return on Assets means that Sinopep generated ¥0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 2.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.8%TTM2.6%+0.1%
TTM2.6%YOY1.6%+1.1%
TTM2.6%5Y1.8%+0.9%
5Y1.8%10Y1.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8%-12.4%+15.2%
TTM2.6%-12.4%+15.0%
YOY1.6%-11.8%+13.4%
5Y1.8%-13.2%+15.0%
10Y1.8%-15.2%+17.0%
4.3.1.3. Return on Equity

Shows how efficient Sinopep is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • 4.7% Return on Equity means Sinopep generated ¥0.05 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 4.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.7%TTM4.4%+0.3%
TTM4.4%YOY2.2%+2.2%
TTM4.4%5Y2.6%+1.8%
5Y2.6%10Y2.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7%-15.9%+20.6%
TTM4.4%-16.6%+21.0%
YOY2.2%-15.2%+17.4%
5Y2.6%-19.0%+21.6%
10Y2.6%-20.5%+23.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Sinopep is operating .

  • Measures how much profit Sinopep makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY11.0%-11.0%
TTM-5Y4.8%-4.8%
5Y4.8%10Y4.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM--316.3%+316.3%
YOY11.0%-208.2%+219.2%
5Y4.8%-367.6%+372.4%
10Y4.8%-483.9%+488.7%
4.3.2.2. Operating Ratio

Measures how efficient Sinopep is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are ¥0.90 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 0.900. The company is less efficient in keeping operating costs low.
  • The TTM is 1.003. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.900TTM1.003-0.103
TTM1.003YOY0.943+0.061
TTM1.0035Y0.773+0.230
5Y0.77310Y0.7730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9002.167-1.267
TTM1.0033.118-2.115
YOY0.9433.194-2.251
5Y0.7734.689-3.916
10Y0.7736.422-5.649
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Sinopep is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.27 means the company has ¥1.27 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 1.275. The company is just able to pay all its short-term debts.
  • The TTM is 1.410. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.275TTM1.410-0.135
TTM1.410YOY1.608-0.198
TTM1.4105Y1.947-0.537
5Y1.94710Y1.9470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2753.586-2.311
TTM1.4103.854-2.444
YOY1.6084.496-2.888
5Y1.9475.971-4.024
10Y1.9476.269-4.322
4.4.3.2. Quick Ratio

Measures if Sinopep is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • A Quick Ratio of 0.46 means the company can pay off ¥0.46 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 0.458. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.450. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.458TTM0.450+0.008
TTM0.450YOY0.846-0.396
TTM0.4505Y1.212-0.761
5Y1.21210Y1.2120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4583.068-2.610
TTM0.4503.312-2.862
YOY0.8464.393-3.547
5Y1.2125.972-4.760
10Y1.2126.490-5.278
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Sinopep assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sinopep to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Sinopep assets are financed with 40.6% credit (debt) and the remaining percentage (100% - 40.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 0.406. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.394. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.406TTM0.394+0.012
TTM0.394YOY0.268+0.126
TTM0.3945Y0.276+0.118
5Y0.27610Y0.2760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4060.340+0.066
TTM0.3940.341+0.053
YOY0.2680.310-0.042
5Y0.2760.363-0.087
10Y0.2760.384-0.108
4.5.4.2. Debt to Equity Ratio

Measures if Sinopep is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sinopep to the Biotechnology industry mean.
  • A Debt to Equity ratio of 68.9% means that company has ¥0.69 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The MRQ is 0.689. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.656. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.689TTM0.656+0.033
TTM0.656YOY0.371+0.286
TTM0.6565Y0.403+0.253
5Y0.40310Y0.4030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6890.387+0.302
TTM0.6560.428+0.228
YOY0.3710.391-0.020
5Y0.4030.451-0.048
10Y0.4030.495-0.092
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Sinopep generates.

  • Above 15 is considered overpriced but always compare Sinopep to the Biotechnology industry mean.
  • A PE ratio of 30.71 means the investor is paying ¥30.71 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The EOD is 24.753. Based on the earnings, the company is fair priced.
  • The MRQ is 30.708. Based on the earnings, the company is overpriced. -1
  • The TTM is 33.979. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD24.753MRQ30.708-5.955
MRQ30.708TTM33.979-3.271
TTM33.979YOY57.195-23.216
TTM33.9795Y57.971-23.992
5Y57.97110Y57.9710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD24.753-2.225+26.978
MRQ30.708-2.782+33.490
TTM33.979-3.265+37.244
YOY57.195-3.409+60.604
5Y57.971-6.283+64.254
10Y57.971-6.819+64.790
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The EOD is -12.032. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.926. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -43.688. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.032MRQ-14.926+2.895
MRQ-14.926TTM-43.688+28.761
TTM-43.688YOY-15.107-28.581
TTM-43.6885Y-14.265-29.423
5Y-14.26510Y-14.2650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.032-3.016-9.016
MRQ-14.926-3.724-11.202
TTM-43.688-3.891-39.797
YOY-15.107-4.438-10.669
5Y-14.265-8.306-5.959
10Y-14.265-9.270-4.995
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Sinopep is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.73 means the investor is paying ¥5.73 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Sinopep-Allsino Biopharmaceutical Co. Ltd. A:

  • The EOD is 4.618. Based on the equity, the company is fair priced.
  • The MRQ is 5.729. Based on the equity, the company is overpriced. -1
  • The TTM is 5.618. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.618MRQ5.729-1.111
MRQ5.729TTM5.618+0.111
TTM5.618YOY3.578+2.039
TTM5.6185Y3.394+2.223
5Y3.39410Y3.3940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.6181.915+2.703
MRQ5.7292.191+3.538
TTM5.6182.397+3.221
YOY3.5782.465+1.113
5Y3.3943.815-0.421
10Y3.3944.512-1.118
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,442,610
Total Liabilities1,803,568
Total Stockholder Equity2,616,679
 As reported
Total Liabilities 1,803,568
Total Stockholder Equity+ 2,616,679
Total Assets = 4,442,610

Assets

Total Assets4,442,610
Total Current Assets1,831,307
Long-term Assets2,611,303
Total Current Assets
Cash And Cash Equivalents 561,512
Short-term Investments 100,000
Net Receivables 557,497
Inventory 521,105
Other Current Assets 25,268
Total Current Assets  (as reported)1,831,307
Total Current Assets  (calculated)1,765,382
+/- 65,924
Long-term Assets
Property Plant Equipment 1,582,635
Goodwill 156,336
Intangible Assets 176,763
Long-term Assets Other 382,443
Long-term Assets  (as reported)2,611,303
Long-term Assets  (calculated)2,298,177
+/- 313,126

Liabilities & Shareholders' Equity

Total Current Liabilities1,436,691
Long-term Liabilities366,877
Total Stockholder Equity2,616,679
Total Current Liabilities
Short Long Term Debt 987,828
Accounts payable 256,592
Other Current Liabilities 2,551
Total Current Liabilities  (as reported)1,436,691
Total Current Liabilities  (calculated)1,246,971
+/- 189,720
Long-term Liabilities
Long term Debt 245,559
Capital Lease Obligations Min Short Term Debt31,496
Long-term Liabilities  (as reported)366,877
Long-term Liabilities  (calculated)277,055
+/- 89,822
Total Stockholder Equity
Retained Earnings 707,604
Total Stockholder Equity (as reported)2,616,679
Total Stockholder Equity (calculated)707,604
+/- 1,909,075
Other
Capital Stock219,780
Common Stock Shares Outstanding 219,780
Net Debt 671,875
Net Invested Capital 3,850,066
Net Working Capital 394,616
Property Plant and Equipment Gross 1,582,635



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
0
1,244,512
0
1,341,354
1,346,384
1,395,573
1,390,544
1,967,255
2,026,843
2,126,906
2,157,127
2,304,683
2,376,711
2,522,299
2,592,700
2,617,301
2,913,221
3,547,246
3,719,261
4,015,461
4,442,610
4,442,6104,015,4613,719,2613,547,2462,913,2212,617,3012,592,7002,522,2992,376,7112,304,6832,157,1272,126,9062,026,8431,967,2551,390,5441,395,5731,346,3841,341,35401,244,5120
   > Total Current Assets 
0
293,735
0
421,362
0
487,908
478,574
1,041,081
1,028,831
1,104,101
1,034,676
1,077,466
1,019,115
1,052,470
1,090,586
980,875
1,039,565
1,494,767
1,548,244
1,721,845
1,831,307
1,831,3071,721,8451,548,2441,494,7671,039,565980,8751,090,5861,052,4701,019,1151,077,4661,034,6761,104,1011,028,8311,041,081478,574487,9080421,3620293,7350
       Cash And Cash Equivalents 
0
58,096
0
65,827
0
69,712
107,670
349,690
540,407
591,876
547,561
546,622
428,805
399,965
478,035
407,713
299,199
749,082
544,180
555,216
561,512
561,512555,216544,180749,082299,199407,713478,035399,965428,805546,622547,561591,876540,407349,690107,67069,712065,827058,0960
       Short-term Investments 
0
0
0
13,000
0
80,000
10,000
356,000
112,000
87,132
45,305
33,000
52,000
43,014
91,000
0
35,000
0
200,000
185,000
100,000
100,000185,000200,000035,000091,00043,01452,00033,00045,30587,132112,000356,00010,00080,000013,000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
127,393
175,100
178,836
245,465
167,886
193,742
302,137
296,195
333,752
487,840
557,497
557,497487,840333,752296,195302,137193,742167,886245,465178,836175,100127,3930000000000
       Other Current Assets 
0
120,336
0
189,825
0
153,201
148,601
125,176
139,488
174,277
27,688
13,426
10,217
20,019
19,400
24,090
26,826
43,271
35,897
18,301
25,268
25,26818,30135,89743,27126,82624,09019,40020,01910,21713,42627,688174,277139,488125,176148,601153,2010189,8250120,3360
   > Long-term Assets 
0
950,777
0
919,992
1,346,384
907,665
911,970
926,175
998,011
1,022,805
1,122,450
1,227,217
1,357,596
1,469,830
1,502,114
1,636,426
1,873,655
2,052,479
2,171,017
2,293,616
2,611,303
2,611,3032,293,6162,171,0172,052,4791,873,6551,636,4261,502,1141,469,8301,357,5961,227,2171,122,4501,022,805998,011926,175911,970907,6651,346,384919,9920950,7770
       Property Plant Equipment 
0
654,902
0
629,366
0
613,735
612,716
631,989
673,899
706,554
772,656
804,594
845,174
988,469
988,564
1,038,282
1,193,511
1,405,036
1,463,723
1,506,057
1,582,635
1,582,6351,506,0571,463,7231,405,0361,193,5111,038,282988,564988,469845,174804,594772,656706,554673,899631,989612,716613,7350629,3660654,9020
       Goodwill 
0
162,199
0
162,199
0
162,199
162,199
162,199
162,199
160,920
160,920
156,336
156,336
156,336
156,336
156,336
156,336
156,336
156,336
156,336
156,336
156,336156,336156,336156,336156,336156,336156,336156,336156,336156,336160,920160,920162,199162,199162,199162,1990162,1990162,1990
       Intangible Assets 
0
89,120
0
86,810
0
92,319
90,654
90,396
102,044
97,794
110,030
108,542
110,887
131,410
132,281
145,270
149,468
142,538
141,416
175,417
176,763
176,763175,417141,416142,538149,468145,270132,281131,410110,887108,542110,03097,794102,04490,39690,65492,319086,810089,1200
> Total Liabilities 
0
405,536
0
453,734
423,252
429,549
383,891
221,961
259,019
318,137
332,814
489,311
526,123
597,412
648,695
694,107
927,683
1,357,942
1,450,907
1,594,893
1,803,568
1,803,5681,594,8931,450,9071,357,942927,683694,107648,695597,412526,123489,311332,814318,137259,019221,961383,891429,549423,252453,7340405,5360
   > Total Current Liabilities 
0
334,296
0
383,459
0
382,210
345,286
194,572
214,210
275,395
291,278
449,021
483,277
551,323
604,121
643,420
870,731
973,335
1,063,598
1,253,633
1,436,691
1,436,6911,253,6331,063,598973,335870,731643,420604,121551,323483,277449,021291,278275,395214,210194,572345,286382,2100383,4590334,2960
       Short-term Debt 
0
146,430
0
223,753
0
219,614
220,230
63,603
60,610
80,911
148,779
302,401
299,965
320,191
418,877
0
0
0
0
0
0
000000418,877320,191299,965302,401148,77980,91160,61063,603220,230219,6140223,7530146,4300
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
148,779
302,401
299,965
320,191
418,877
428,078
488,171
546,019
681,651
817,603
987,828
987,828817,603681,651546,019488,171428,078418,877320,191299,965302,401148,7790000000000
       Accounts payable 
0
147,943
0
116,673
0
106,900
86,306
87,788
87,073
128,129
120,515
115,451
145,162
168,941
147,047
166,780
278,378
300,575
242,313
233,575
256,592
256,592233,575242,313300,575278,378166,780147,047168,941145,162115,451120,515128,12987,07387,78886,306106,9000116,6730147,9430
       Other Current Liabilities 
0
33,401
0
29,300
0
40,051
22,001
33,046
63,467
66,356
21,985
31,170
38,150
62,192
38,197
2,672
997
1,241
3,143
1,834
2,551
2,5511,8343,1431,2419972,67238,19762,19238,15031,17021,98566,35663,46733,04622,00140,051029,300033,4010
   > Long-term Liabilities 
0
71,240
0
70,275
423,252
47,338
38,605
27,389
44,809
42,742
41,536
40,290
42,846
46,089
44,575
50,687
56,951
384,607
387,308
341,260
366,877
366,877341,260387,308384,60756,95150,68744,57546,08942,84640,29041,53642,74244,80927,38938,60547,338423,25270,275071,2400
> Total Stockholder Equity
0
834,287
0
885,484
920,996
963,344
1,004,936
1,743,990
1,767,848
1,811,383
1,828,027
1,815,372
1,834,129
1,910,226
1,931,472
1,910,011
1,971,192
2,170,268
2,250,062
2,394,350
2,616,679
2,616,6792,394,3502,250,0622,170,2681,971,1921,910,0111,931,4721,910,2261,834,1291,815,3721,828,0271,811,3831,767,8481,743,9901,004,936963,344920,996885,4840834,2870
   Common Stock
0
159,888
0
159,888
0
159,888
159,888
213,184
213,184
213,184
213,184
213,184
213,184
213,184
213,184
0
0
0
0
0
0
000000213,184213,184213,184213,184213,184213,184213,184213,184159,888159,8880159,8880159,8880
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
635,412
0
638,222
920,996
643,259
645,160
1,319,191
1,321,184
1,331,899
1,332,450
1,333,032
1,333,428
1,337,095
1,337,328
0
0
0
0
0
0
0000001,337,3281,337,0951,333,4281,333,0321,332,4501,331,8991,321,1841,319,191645,160643,259920,996638,2220635,4120



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,033,548
Cost of Revenue-403,395
Gross Profit630,153630,153
 
Operating Income (+$)
Gross Profit630,153
Operating Expense-801,497
Operating Income232,051-171,344
 
Operating Expense (+$)
Research Development124,889
Selling General Administrative118,399
Selling And Marketing Expenses0
Operating Expense801,497243,288
 
Net Interest Income (+$)
Interest Income6,208
Interest Expense-16,085
Other Finance Cost-337
Net Interest Income-10,214
 
Pretax Income (+$)
Operating Income232,051
Net Interest Income-10,214
Other Non-Operating Income Expenses0
Income Before Tax (EBT)173,127232,051
EBIT - interestExpense = -16,085
162,936
179,021
Interest Expense16,085
Earnings Before Interest and Taxes (EBIT)0189,212
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax173,127
Tax Provision-7,674
Net Income From Continuing Ops165,453165,453
Net Income162,936
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net010,214
 

Technical Analysis of Sinopep
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sinopep. The general trend of Sinopep is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sinopep's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 57.69 < 59.22 < 68.18.

The bearish price targets are: 52.02 > 48.54 > 48.30.

Tweet this
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current macd is 0.93119051.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sinopep price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sinopep. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sinopep price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Moving Average Convergence/Divergence (MACD) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current adx is 17.58.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sinopep shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current sar is 49.71.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current rsi is 65.76. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Relative Strength Index (RSI) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sinopep price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Stochastic Oscillator ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current cci is 187.87.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Commodity Channel Index (CCI) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current cmo is 41.07.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Chande Momentum Oscillator (CMO) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current willr is -7.24832215.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Williams %R ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current atr is 2.05191644.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Average True Range (ATR) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current obv is 100,118,016.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily On-Balance Volume (OBV) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sinopep-Allsino Biopharmaceutical Co. Ltd. A. The current mfi is 75.20.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Money Flow Index (MFI) ChartSinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-12-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sinopep-Allsino Biopharmaceutical Co. Ltd. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.763
Ma 20Greater thanMa 5050.940
Ma 50Greater thanMa 10050.824
Ma 100Greater thanMa 20053.214
OpenGreater thanClose53.460
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Sinopep with someone you think should read this too:
  • Are you bullish or bearish on Sinopep? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sinopep? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sinopep-Allsino Biopharmaceutical Co. Ltd. A

I send you an email if I find something interesting about Sinopep-Allsino Biopharmaceutical Co. Ltd. A.


Comments

How you think about this?

Leave a comment

Stay informed about Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

Receive notifications about Sinopep-Allsino Biopharmaceutical Co. Ltd. A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.